Nanotherapeutics Submits Investigational New Drug Application to FDA for Clinical Testing of Oral Drug to Treat Radiation Exposure
8/30/2010 9:34:31 AM
ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.